RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+10.05%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$630M
AUM Growth
+$630M
(+12%)
Cap. Flow
+$14.3M
Cap. Flow
% of AUM
2.28%
Top 10 Holdings %
Top 10 Hldgs %
30.71%
Holding
120
New
23
Increased
22
Reduced
39
Closed
13
Top Buys
| 1 |
SHPG
Shire pic
SHPG
|
$26.6M |
| 2 |
Merck
MRK
|
$12.5M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$12.4M |
| 4 |
AGN
Allergan plc
AGN
|
$6.33M |
| 5 |
UnitedHealth
UNH
|
$6.3M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$20M |
| 2 |
Pfizer
PFE
|
$13.2M |
| 3 |
Medtronic
MDT
|
$11M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$8.04M |
| 5 |
CPHD
Cepheid Inc
CPHD
|
$8M |
Sector Composition
| 1 | Healthcare | 86.01% |
| 2 | Financials | 0.83% |
| 3 | Technology | 0.09% |
| 4 | Energy | 0.06% |
| 5 | Industrials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SHPG
1
DELISTED
Shire pic
SHPG
| $26.6M | 4.22% | +409,858 | New | +$26.6M |
|
2
Eli Lilly
LLY
$657B
| $20.5M | 3.25% | 255,000 +20,000 | +9% | +$1.61M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $19.8M | 3.15% | 161,702 -61,380 | -28% | -$7.52M |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $19.4M | 3.09% | 186,000 -13,000 | -7% | -$1.36M |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $18.3M | 2.91% | 79,500 +27,500 | +53% | +$6.33M |
|
|
6
UnitedHealth
UNH
$281B
| $18.2M | 2.89% | 130,000 +45,000 | +53% | +$6.3M |
|
7
Biogen
BIIB
$19.4B
| $17.8M | 2.83% | 57,000 -23,000 | -29% | -$7.2M |
|
8
Incyte
INCY
$16.5B
| $17.4M | 2.77% | 185,000 +15,000 | +9% | +$1.41M |
|
9
CVS Health
CVS
$92.8B
| $14.2M | 2.26% | 160,000 +40,000 | +33% | +$3.56M |
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $13M | 2.06% | 140,000 -10,000 | -7% | -$925K |
|
11
Bristol-Myers Squibb
BMY
$96B
| $12.8M | 2.03% | 237,000 +100,000 | +73% | +$5.39M |
|
|
12
Merck
MRK
$210B
| $12.5M | 1.98% | +200,000 | New | +$12.5M |
|
|
13
Teva Pharmaceuticals
TEVA
$21.1B
| $12.4M | 1.97% | +270,000 | New | +$12.4M |
|
|
14
Regeneron Pharmaceuticals
REGN
$61.5B
| $11.9M | 1.88% | 29,500 -20,000 | -40% | -$8.04M |
|
15
Zimmer Biomet
ZBH
$21B
| $11.1M | 1.76% | 85,000 +14,000 | +20% | +$1.82M |
|
16
Cigna
CI
$80.3B
| $10.9M | 1.74% | 84,000 -15,000 | -15% | -$1.95M |
|
|
ABMD
17
DELISTED
Abiomed Inc
ABMD
| $10.9M | 1.74% | 85,000 -20,000 | -19% | -$2.57M |
|
|
ARIA
18
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $9.24M | 1.47% | 675,000 +50,000 | +8% | +$685K |
|
19
Amgen
AMGN
$155B
| $9.17M | 1.46% | 55,000 -6,500 | -11% | -$1.08M |
|
20
Alnylam Pharmaceuticals
ALNY
$58.5B
| $8.81M | 1.4% | 130,000 -65,000 | -33% | -$4.41M |
|
21
HCA Healthcare
HCA
$94.5B
| $8.32M | 1.32% | 110,000 +10,000 | +10% | +$756K |
|
22
Alkermes
ALKS
$4.78B
| $8.26M | 1.31% | 175,599 +40,000 | +29% | +$1.88M |
|
|
ESRX
23
DELISTED
Express Scripts Holding Company
ESRX
| $7.83M | 1.24% | 111,000 -5,000 | -4% | -$353K |
|
24
Exelixis
EXEL
$10.1B
| $7.67M | 1.22% | 600,000 -200,000 | -25% | -$2.56M |
|
25
Jazz Pharmaceuticals
JAZZ
$7.75B
| $7.29M | 1.16% | 60,000 -10,000 | -14% | -$1.21M |
|